SMS Pharmaceuticals · tone and specificity signals across the available quarters.
Language signals
FY27 was a year of rebuilding the foundation for the next phase of growth. Over the last 3 years, we have invested significantly in backward integration, product registrations, plant engineering, and capacity expansion. Much of this work requires time before it translates to commercial results.
The main important driver will be the backward integration because for a very key important product like ibuprofen if we've not backward integrated like we've not taken the skull of backward integration a couple of years back we would have probably been in a very bad situation now because of the current market scenarios.
Our all-time high EBITDA margin was around 22% and definitely we are targeting that this year and in subsequent years we're trying to probably exceed that.